Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Deloitte
Queensland Health
QuintilesIMS
Citi
Medtronic
US Department of Justice
Covington
McKinsey

Generated: April 20, 2018

DrugPatentWatch Database Preview

Vismodegib - Generic Drug Details

« Back to Dashboard

What are the generic sources for vismodegib and what is the scope of vismodegib patent protection?

Vismodegib
is the generic ingredient in one branded drug marketed by Genentech and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vismodegib has forty-three patent family members in twenty-two countries.

One supplier is listed for this compound.
Summary for vismodegib
Pharmacology for vismodegib
Synonyms for vismodegib
085G559
2-Chloranyl-~{n}-(4-Chloranyl-3-Pyridin-2-Yl-Phenyl)-4-Methylsulfonyl-Benzamide
2-chloro-n-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)benzamide
2-Chloro-N-(4-chloro-3-(2-pyridl)phenyl)-4-(methylsulfonyl)benzamide
2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methyl sulfonyl)benzamide
2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide
2-chloro-N-(4-chloro-3-pyridin-2-yl-phenyl)-4-methanesulfonyl-benzamide
2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide
2-CHLORO-N-[4-CHLORO-3-(2-PYRIDINYL)PHENYL]-4-(METHYLSULFONYL)-BENZAMIDE
2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)benzamide
2-chloro-N-[4-chloro-3-(2-pyridyl)phenyl]-4-methylsulfonyl-benzamide
2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide
2-chloro-N~1~-[4-chloro-3-(2-pyridyl)phenyl]-4-(methylsulfonyl)benzamide
25X868M3DS
4CA-1325
879085-55-9
A10467
AB0008125
AB01565813_02
ABP000894
AC-26969
AJ-103831
AK-77261
AKOS015966534
AN-471
ANW-60962
AOB1040
AS-14066
AX8167197
BC660083
BCP9000713
BCPP000223
BDBM50249522
Benzamide, 2-chloro-N-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)-
BENZAMIDE, 2-CHLORO-N-[4-CHLORO-3-(2-PYRIDINYL)PHENYL]-4-(METHYLSULFONYL)-
BG0661
BPQMGSKTAYIVFO-UHFFFAOYSA-N
C19H14Cl2N2O3S
C538724000
CHEBI:66903
CHEMBL473417
CS-0255
CTK8B8648
CUR-691
D03EDQ
D09992
D0LB7J
DB08828
DTXSID40236689
Erivedge
Erivedge (TN)
FT-0675833
GD 0449|||2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)benzamide
GDC 0449
GDC-0449
GDC-0449 - Selumetinib
GDC-0449 (Vismodegib)
GDC-0449, GDC0449, GDC 0449, 879085-55-9
GDC-0449,Vismodegib
GDC-0449,Vismodegib, HhAntag691
GDC-0449(Vismodegib)
GDC-0449(Vismodegib)/GDC0449
GDC-449
GDC0449
GTPL6975
HE067811
HE401106
Hh-Antag691
HhAntag691
HMS3604K16
HMS3654E17
HSDB 8130
HY-10440
J-509076
J90022
KB-308771
KB-81450
KS-000000BH
MCULE-6680076172
MFCD12407408
MLS006012035
MolPort-009-679-417
NCGC00242497-01
NCGC00242497-02
NSC 747691
NSC-747691
NSC-755986
NSC747691
NSC755986
PB15086
PubChem19137
Q-2305
QCR-40
R 3616
R-3616
RG-3616
RG3616
RL05479
s1082
SC-87729
SCHEMBL302587
SMR004703564
SR-01000941574
SR-01000941574-1
ST24040458
TC-149707
UNII-25X868M3DS
V-4050
VIS
Vismodegib (GDC-0449)
Vismodegib (SHH inhibitor)
Vismodegib (USAN/INN)
Vismodegib [USAN:INN]
Vismodegib, free base
vismodegibum
X4669
ZINC40899447

US Patents and Regulatory Information for vismodegib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genentech ERIVEDGE vismodegib CAPSULE;ORAL 203388-001 Jan 30, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Genentech ERIVEDGE vismodegib CAPSULE;ORAL 203388-001 Jan 30, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for vismodegib

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,321,761 Pyridyl inhibitors of hedgehog signalling ➤ Sign Up
9,790,183 Pyridyl inhibitors of hedgehog signalling ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for vismodegib

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0 12-2013 Slovakia ➤ Sign Up PRODUCT NAME: VISMODEGIB; REGISTRATION NO/DATE: EU/1/13/848/001 20130712
2013 00050 Denmark ➤ Sign Up PRODUCT NAME: VISMODEGIB; NAT. REG. NO/DATE: EU71/13/848 20130712; FIRST REG. NO/DATE: CH 62497 20130530
14/002 Ireland ➤ Sign Up PRODUCT NAME: ERIVEDGE-VISMODEGIB OR A SALT OR SOLVATE THEREOF; NAT REGISTRATION NO/DATE: EU/1/13/848 20130712; FIRST REGISTRATION NO/DATE: 62497 01 20130530
00614 Netherlands ➤ Sign Up PRODUCT NAME: VISMODEGIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/13/848 20130712
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Moodys
US Department of Justice
Chubb
McKesson
Harvard Business School
Argus Health
US Army
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.